JP2023505222A5 - - Google Patents

Info

Publication number
JP2023505222A5
JP2023505222A5 JP2022533442A JP2022533442A JP2023505222A5 JP 2023505222 A5 JP2023505222 A5 JP 2023505222A5 JP 2022533442 A JP2022533442 A JP 2022533442A JP 2022533442 A JP2022533442 A JP 2022533442A JP 2023505222 A5 JP2023505222 A5 JP 2023505222A5
Authority
JP
Japan
Prior art keywords
tumor
lesion
cancer
pharmaceutical product
product according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022533442A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023505222A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/063444 external-priority patent/WO2021113734A1/en
Publication of JP2023505222A publication Critical patent/JP2023505222A/ja
Publication of JP2023505222A5 publication Critical patent/JP2023505222A5/ja
Pending legal-status Critical Current

Links

JP2022533442A 2019-12-06 2020-12-04 免疫増強および腫瘍処置のための方法 Pending JP2023505222A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962945053P 2019-12-06 2019-12-06
US62/945,053 2019-12-06
PCT/US2020/063444 WO2021113734A1 (en) 2019-12-06 2020-12-04 Methods for enhancing immunity and tumor treatment

Publications (2)

Publication Number Publication Date
JP2023505222A JP2023505222A (ja) 2023-02-08
JP2023505222A5 true JP2023505222A5 (cg-RX-API-DMAC7.html) 2023-12-12

Family

ID=73856374

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022533442A Pending JP2023505222A (ja) 2019-12-06 2020-12-04 免疫増強および腫瘍処置のための方法

Country Status (6)

Country Link
US (1) US20230028062A1 (cg-RX-API-DMAC7.html)
EP (1) EP4069300A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023505222A (cg-RX-API-DMAC7.html)
CN (1) CN115052631A (cg-RX-API-DMAC7.html)
TW (1) TW202133886A (cg-RX-API-DMAC7.html)
WO (1) WO2021113734A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2999358T3 (en) 2015-08-18 2025-02-25 Rakuten Medical Inc Phthalocyanine dye conjugates and their storage
US12704501B2 (en) 2019-03-29 2026-08-11 Rakuten Medical, Inc. Methods for photoimmunotherapy and related biomarkers
WO2022182483A1 (en) * 2021-02-02 2022-09-01 Rakuten Medical, Inc. Methods for local and systemic treatment of cancers, tumors and tumor cells
CA3252736A1 (en) * 2022-02-18 2023-08-24 Rakuten Medical, Inc. Anti-PD-L1 (Programmed Death-Ligand 1) Antibody Molecules, Coding Polynucleotides, and Methods of Use
CN115364238B (zh) * 2022-08-16 2024-02-02 山东大学 一种阿特珠单抗-mmad结合物及其制备方法与应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
ES2992591T3 (en) * 2015-08-18 2024-12-16 Rakuten Medical Inc Compositions, combinations and related methods for photoimmunotherapy
ES2999358T3 (en) * 2015-08-18 2025-02-25 Rakuten Medical Inc Phthalocyanine dye conjugates and their storage
CN109863346A (zh) 2016-10-25 2019-06-07 乐天医药生技股份有限公司 用于光免疫治疗的光漫射装置
US10416366B2 (en) 2016-10-25 2019-09-17 Rakuten Medical, Inc. Light diffusing devices for use in photoimmunotherapy
JP2020508323A (ja) * 2017-02-23 2020-03-19 ラクテン メディカル インコーポレイテッド 光免疫療法のための治療用組成物および関連する方法
US12704501B2 (en) * 2019-03-29 2026-08-11 Rakuten Medical, Inc. Methods for photoimmunotherapy and related biomarkers
CN114423453A (zh) * 2019-07-30 2022-04-29 乐天医药生技股份有限公司 使用偶联的抗cd25酞菁和抗pd1的基于光化学的癌症疗法近红外(nir)光免疫疗法(pit)

Similar Documents

Publication Publication Date Title
Lee et al. Advancements in small cell lung cancer
Hu et al. Combined radiation therapy and immune checkpoint blockade therapy for breast cancer
Huinen et al. Anti-angiogenic agents—overcoming tumour endothelial cell anergy and improving immunotherapy outcomes
Du et al. PD-1 modulates radiation-induced cardiac toxicity through cytotoxic T lymphocytes
Chang et al. Interventional therapy combined with immune checkpoint inhibitors: emerging opportunities for cancer treatment in the era of immunotherapy
Hovhannisyan et al. CAR T cell-based immunotherapy and radiation therapy: potential, promises and risks
Chen et al. Driving CARs on the uneven road of antigen heterogeneity in solid tumors
Ferris et al. Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation
Al Jarroudi et al. Anti-programmed cell death protein 1 (PD-1) immunotherapy for metastatic hepatocellular carcinoma after liver transplantation: a report of three cases
Golden et al. Radiotherapy and immunogenic cell death
Cushman et al. Combining radiation plus immunotherapy to improve systemic immune response
Gupta et al. Clinical activity of ipilimumab plus nivolumab in patients with metastatic non–clear cell renal cell carcinoma
Cai et al. Apatinib enhanced anti-PD-1 therapy for colon cancer in mice via promoting PD-L1 expression
Jason et al. Integration of radiation and immunotherapy in breast cancer-treatment implications
Gervaso et al. Immunotherapy in the neoadjuvant treatment of gastrointestinal tumors: is the time ripe?
JP2022543765A5 (cg-RX-API-DMAC7.html)
JP7614690B1 (ja) 腫瘍微小環境をターゲットとする光免疫療法に用いる医薬組成物、治療効果確認のためのマーカー、及び検査方法
CN114173794A (zh) Pdl1阳性nk细胞癌症治疗
Amin et al. Multi-institutional report on toxicities of concurrent nivolumab and radiation therapy
WO2023095929A1 (ja) 悪性腫瘍治療薬
Chavez et al. Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemia
Fleischmann et al. Radioimmunotherapy: future prospects from the perspective of brachytherapy
Serre et al. Brachytherapy: Perspectives for combined treatments with immunotherapy
Gorwitz et al. Zolbetuximab-clzb: targeting Claudin 18.2 in advanced gastric and gastroesophageal adenocarcinoma
Xia et al. Irradiation enhanced the effects of PD-1 blockade in brain metastatic osteosarcoma